All In Biotech

Drug Trial Radar · NCT07230106

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

A Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of HS-20093 or SHR2554 Tablets in Combination With Novel Hormonal Agents in Participants With Metastatic Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

218

Planned (sponsor's estimate)

Start

Dec 8, 2025

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.

Conditions

  • Prostate Cancer

Interventions

  • HS-20093 for InjectionDrug

    HS-20093 for injection.

  • SHR3680 TabletDrug

    SHR3680 tablet.

  • Abiraterone TabletDrug

    Abiraterone tablet.

  • SHR2554 TabletDrug

    SHR2554 tablet.

  • Enzalutamide TabletDrug

    Enzalutamide tablet.

  • Darotamine CapsuleDrug

    Darotamine capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: 6-month undetectable Prostate Specific Antigen (PSA) rate.Time frame: 6 months.
  2. Cohort 2: Prostate Specific Antigen (PSA) response rate.Time frame: About 2 years.
  3. Cohort 2: Adverse events (AEs).Time frame: About 2 years.
  4. Cohort 2: Dose-limiting toxicity (DLT).Time frame: About 28 days.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.